Scholars@Duke

Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases.

Publication ,  Journal Article
Joy, MS; Frye, RF; Stubbert, K; Brouwer, KR; Falk, RJ; Kharasch, ED
Published in: J Clin Pharmacol
June 2010
Published version (DOI) Link to item

Duke Scholars

Evan Kharasch
Author Evan Kharasch Anesthesiology, General, Vascular, High Risk Transplant & Cr ...
Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Pharmacol

DOI

10.1177/0091270009353031

EISSN

1552-4604

Publication Date

June 2010

Volume

50

Issue

6

Start / End Page

714 / 720

Location

England

Related Subject Headings

  • Stereoisomerism
  • Phenotype
  • Pharmacology & Pharmacy
  • Oxidoreductases, N-Demethylating
  • Middle Aged
  • Male
  • Lupus Nephritis
  • Humans
  • Female
  • Cytochrome P-450 CYP2B6
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Joy, M. S., Frye, R. F., Stubbert, K., Brouwer, K. R., Falk, R. J., & Kharasch, E. D. (2010). Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. J Clin Pharmacol, 50(6), 714–720. https://doi.org/10.1177/0091270009353031
Joy, Melanie S., Reginald F. Frye, Kristi Stubbert, Kim R. Brouwer, Ronald J. Falk, and Evan D. Kharasch. “Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases.” J Clin Pharmacol 50, no. 6 (June 2010): 714–20. https://doi.org/10.1177/0091270009353031.
Joy MS, Frye RF, Stubbert K, Brouwer KR, Falk RJ, Kharasch ED. Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. J Clin Pharmacol. 2010 Jun;50(6):714–20.
Joy, Melanie S., et al. “Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases.” J Clin Pharmacol, vol. 50, no. 6, June 2010, pp. 714–20. Pubmed, doi:10.1177/0091270009353031.
Joy MS, Frye RF, Stubbert K, Brouwer KR, Falk RJ, Kharasch ED. Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. J Clin Pharmacol. 2010 Jun;50(6):714–720.

Published In

J Clin Pharmacol

DOI

10.1177/0091270009353031

EISSN

1552-4604

Publication Date

June 2010

Volume

50

Issue

6

Start / End Page

714 / 720

Location

England

Related Subject Headings

  • Stereoisomerism
  • Phenotype
  • Pharmacology & Pharmacy
  • Oxidoreductases, N-Demethylating
  • Middle Aged
  • Male
  • Lupus Nephritis
  • Humans
  • Female
  • Cytochrome P-450 CYP2B6